International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Review on Development and Validation of Stability Indicating Method RP-HPLC on Marketed Formulation

Amit Agalawe[1], Priyanka Deshpande[2], Anupriya Gite[3]

ABSTRACT:

High-Performance Liquid Chromatography (HPLC) is one of the most important and widely used techniques in pharmaceutical analysis. It is highly effective in separating, identifying, and quantifying various components in complex drug formulations. Among its different types, Reverse Phase HPLC (RP-HPLC) is especially preferred due to its accuracy, reproducibility, and ability to handle compounds with different chemical properties.

This study focused on the development and validation of a stability-indicating RP-HPLC method for the analysis of a marketed tablet formulation. The main goal was to create a reliable method that can accurately measure the active pharmaceutical ingredient (API) even in the presence of its degradation products or formulation excipients. Several steps were involved in the method development, including the selection of mobile phase, column type, detection wavelength, and flow rate. The method was optimized through trials and adjusted to ensure proper separation and sharp, symmetrical peaks.

Standard solutions were prepared using acetonitrile, methanol, and water mixtures, followed by sonication and filtration. Chromatographic separation was achieved using an Acclaimed mixed-mode HILIC-1 column, with a water-acetonitrile mobile phase and UV detection at 230 nm. The developed method was tested for linearity, precision, accuracy, robustness, and specificity following ICH guidelines.

Validation studies confirmed that the method was linear over a wide concentration range, accurate in drug recovery, and precise under both intra-day and inter-day conditions. Robustness testing showed that minor changes in analytical parameters did not significantly affect the results. The method also passed system suitability tests, indicating strong reliability and performance.

Overall, this RP-HPLC method proved to be efficient and suitable for routine analysis of the marketed tablet formulation. It ensures quality control by accurately quantifying the API and detecting any degradation products, making it valuable for both manufacturing and regulatory compliance.

INTRODUCTION

High-Performance Liquid Chromatography (HPLC) is a cornerstone analytical technique in pharmaceutical analysis, renowned for its ability to separate, identify, and quantify components within complex mixtures. Its high sensitivity, precision, and adaptability make it indispensable for ensuring drug purity, potency, and safety. Among the various HPLC techniques, Reverse Phase HPLC (RP-HPLC) is particularly favored due to its robustness and effectiveness in handling compounds of varying polarities. Developing a stability-indicating RP-HPLC method is crucial for assessing the stability of pharmaceutical products. Such methods are designed to detect the active pharmaceutical ingredient (API) and its potential degradation products, providing essential insights into the drug's shelf life and

appropriate storage conditions. The development process involves optimizing chromatographic parameters, including sample preparation, mobile phase composition, column selection, and detection settings, to achieve accurate and reproducible results.

Validation of the developed method is a fundamental requirement to ensure its reliability and compliance with regulatory standards. According to the International Council for Harmonisation (ICH) guidelines, key validation parameters include specificity, linearity, accuracy, precision, detection limit, quantitation limit, robustness, and system suitability. Implementing a comprehensive validation policy is essential for pharmaceutical industries to comply with Good Manufacturing Practice (GMP) standards.

In the context of solid oral dosage forms, tablets are among the most prevalent, offering advantages such as accurate dosing, portability, and ease of administration. They are formulated by compressing APIs with suitable excipients into a solid form, ensuring consistent drug delivery and patient compliance.

Ensuring the stability and efficacy of APIs within tablet formulations is vital for delivering consistent therapeutic outcomes.

This article focuses on the development and validation of a stability-indicating RP-HPLC method for analyzing a marketed tablet formulation. Such methods are essential for detecting
potential degradation products and assessing the stability of the API, thereby guaranteeing the safety and therapeutic effectiveness of the pharmaceutical product.

HPLC INTRODUCTION:

High-Performance Liquid Chromatography (HPLC) is a powerful and precise analytical method used for separating, identifying, and quantifying individual components in a mixture. It has become a cornerstone in chemical and biochemical analysis due to its high resolution, reproducibility, and adaptability across a wide range of sample types. Its applications span pharmaceutical development, clinical diagnostics, food safety, environmental monitoring, and more.



Construction of an HPLC System

An HPLC system is composed of several integrated components, each performing a specific role to ensure accurate and efficient chromatographic analysis. Below is a breakdown of the key parts and their functions:

1. Solvent Reservoirs (Mobile Phase Containers)

These containers hold the mobile phase solvents, which are typically mixtures of water, organic solvents (like methanol or acetonitrile), and buffer solutions. The choice of solvent depends on the nature of the analytes and the stationary phase. Solvents must be degassed to remove air bubbles that could interfere with flow and detection.

2. Pump

The pump delivers the mobile phase at a constant and precisely controlled flow rate through the system. It is responsible for generating the high pressure (typically 500–6000 psi) required for moving the mobile phase through the packed column. Most modern systems use reciprocating piston pumps for their consistency and high-pressure capability.

3. Injector

The injector introduces the sample into the flow of the mobile phase. This can be done manually through a loop injector or automatically via an autosampler. The injector ensures that a reproducible volume of the sample enters the system without disturbing the flow or pressure.





4. Column

The column is the heart of the HPLC system, packed with the stationary phase—usually silica-based particles modified with various chemical groups (e.g., C18 for reverse-phase chromatography). It is where the actual separation of analytes occurs based on their interactions with the stationary and mobile phases. Column dimensions and particle sizes can vary depending on the application.

5. Detector

Once the components are separated in the column, they pass through a detector that measures their concentration based on physical or chemical properties.

Detector	Main Use	Key Advantage
UV-Visible (UV)	For compounds absorbing UV light	High sensitivity, simple, cost-effective
Photodiode Array (PDA)	For spectral analysis and peak purity check	Detects multiple wavelengths simultaneously
Fluorescence	For naturally fluorescent or tagged compounds	Extremely high sensitivity, low detection limits
Mass Spectrometry (MS)	For molecular weight and structure analysis	High selectivity and accurate dentification
Refractive Index (RI)	For compounds with no UV absorbance	Universal detector, non-destructive

6. Data Acquisition System

The detector is connected to a computer system or an integrated processor that records the detector signals and generates chromatograms. Modern software allows for real-time analysis, peak integration, quantitative calculations, and data storage.

7. Waste Container

After detection, the mobile phase and analytes are directed to a waste reservoir. In some setups, particularly those using hazardous solvents, waste management is critical to ensure safety and environmental compliance.

The HPLC technique has the characteristics listed below:

- Higher solution, small diameter, stainless steel, and glass column
- Quick analysis
- Significantly higher mobile phase pressure

METHOD DEVELOPMENT

Analytical method development and validation are essential components in the research, development, and manufacturing of pharmaceutical products. These methods are employed to ensure the identity, purity, potency, and overall performance of drug substances and formulations. A well-developed and validated analytical method is fundamental for quality control, regulatory compliance, and ensuring patient safety.

When developing an HPLC method, multiple factors must be taken into consideration. The process typically begins with the collection and evaluation of the analyte's physicochemical properties, such as pKa, log P (partition coefficient), solubility, and molecular structure. This foundational knowledge aids in selecting the appropriate chromatographic conditions and detection mode—for example, determining the optimal wavelength in UV detection.

A significant portion of method development in pharmaceuticals is devoted to creating and validating stability-indicating methods. These methods are designed to separate and quantify not only the active pharmaceutical ingredient (API) but also any related substances, such as synthetic intermediates, reaction by-products, degradants, and impurities.

Key Steps in HPLC Method Development

1. **Understanding the Physicochemical Properties of the Drug Molecule**

This involves studying the molecule's structure, polarity, solubility profile, ionization constant (pKa), and lipophilicity. These parameters influence the selection of the mobile phase, pH, column type, and detection strategy.

2. **Setting Up Initial HPLC Conditions**

Preliminary conditions such as mobile phase composition, flow rate, stationary phase type (e.g., C18), detection wavelength, and column temperature are selected based on prior knowledge or literature. Reverse phase is often the first choice due to its versatility.

3. **Preparation of Sample Solution**

A suitable concentration of the analyte is prepared in a compatible solvent. Filtration and degassing are critical to prevent column blockage or detector noise. Sample stability must also be ensured throughout the analysis.

4. **Method Optimization**

Fine-tuning of the chromatographic parameters is performed to improve peak shape, resolution, run time, and reproducibility. This includes adjusting the mobile phase ratio, gradient conditions, buffer strength and pH, and temperature. The aim is to achieve baseline separation of all relevant components.

5. **Method Validation**

Once the method shows consistent performance, it is validated as per ICH (International Council for Harmonisation) guidelines. Parameters such as accuracy, precision, linearity, specificity, robustness, limit of detection (LOD), and limit of quantification (LOQ) are evaluated to confirm the method's reliability for routine use.

Validation of HPLC Methods

The validation of analytical methods is an essential part of pharmaceutical development and regulatory compliance. For stability-indicating RP-HPLC methods, validation ensures that the method is capable of

accurately measuring the active pharmaceutical ingredient (API) in the presence of degradation products, excipients, and impurities under various stress conditions.

The validation process is performed in accordance with ICH guidelines, primarily ICH Q2(R1), which outlines the key parameters to assess method performance. A validated method must consistently deliver accurate, precise, and specific results, even when minor changes are introduced into the procedure or environment.

Key Parameters in Method Validation

1. **Specificity**

Ensures the method can distinctly measure the analyte of interest, even in the presence of degradation products, excipients, or impurities. In stability-indicating methods, specificity is demonstrated through forced degradation studies.

2. **Linearity**

Demonstrates that the response is directly proportional to analyte concentration within a specified range. Typically evaluated using a calibration curve, with a correlation coefficient (R^2) ≥ 0.999 considered acceptable.

3. **Accuracy (Recovery Studies)**

Refers to the closeness of measured values to the true values. It is assessed by spiking known concentrations of the analyte into the matrix and calculating the percentage recovery, usually at three concentration levels (e.g., 80%, 100%, 120%).

4. **Precision**

Repeatability (Intra-day Precision): Assessed under the same conditions over a short interval.

Intermediate Precision (Inter-day): Evaluated across different days, analysts, or equipment. Precision is expressed as %RSD (relative standard deviation), with values typically <2% for good methods.

5. **Limit of Detection (LOD)**

The lowest concentration of analyte that can be detected but not necessarily quantified. It is often calculated using the signal-to-noise ratio method (S/N ≈ 3:1).

6. **Limit of Quantitation (LOQ)**

The smallest amount of analyte that can be quantitatively determined with acceptable accuracy and precision, usually at a signal-to-noise ratio of 10:1.

7. **Robustness**

Assesses the method's reliability under small, intentional variations in parameters such as pH, temperature, flow rate, or mobile phase composition. A robust method maintains its performance despite such changes.

8. **System Suitability Testing**

Conducted before sample analysis to ensure the chromatographic system is performing adequately. Parameters typically evaluated include:

Retention time (tR)

Theoretical plate number (N)

Tailing factor (Tf) – should be close to 1

Resolution (Rs) – ≥2 between closely eluting peaks

Capacity factor (k′) – typically between 1 and 10

9. Stability-Indicating Capability

Proven through forced degradation studies, where the API is subjected to stress conditions (acid/base hydrolysis, oxidative, thermal, and photolytic conditions). The method must clearly separate the drug from its degradation products, ensuring no interference at the analyte's retention time.

MATERIALS AND METHODS

1. Reagents

High-Performance Liquid Chromatography (HPLC) grade acetonitrile and deionized water were procured from Merck, Mumbai, India. Nylon membrane filters with pore sizes of 0.20 µm and 0.45 µm were obtained from UltraChrom Innovatives Pvt. Ltd., India. All other chemicals and reagents used were of analytical grade, ensuring the reliability and accuracy of the analytical procedures.

2. Standard Stock Solutions

A standard stock solution of the marketed formulation was prepared by accurately dissolving 10 mg of the active pharmaceutical ingredient (API) in a mixture of acetonitrile, methanol, and water in a 4:4:2 (v/v/v) ratio within a 20 mL volumetric flask. The solution was sonicated for 10–20 minutes to ensure complete dissolution and then filtered through a 0.20 µm nylon membrane filter to remove any particulate matter. Subsequent serial dilutions were performed as required for validation studies, maintaining consistency and precision in the analytical measurements.

3. Chromatographic Conditions

Chromatographic separation was performed using an Acclaimed mixed-mode HILIC-1 column (150 mm × 4.6 mm, 5 µm particle size). An isocratic elution was employed with a mobile phase consisting of water and acetonitrile in a 40:60 (v/v) ratio. The mobile phase was filtered through a 0.2 µm nylon membrane filter and degassed in an ultrasonic bath for 10–20 minutes prior to use to prevent air bubble formation and ensure consistency. The flow rate was set at 1.1 mL/min, and the column temperature was maintained at 28 °C to optimize the separation process. An ultraviolet (UV) detector was set at a wavelength of 230 nm for the detection of the analyte, and an injection volume of 20 µL was used for each analysis, ensuring reproducibility and sensitivity.

4. Sample Preparation for Drug Recovery Studies

A quantity of 10–20 tablets of the marketed formulation, each containing 500 mg of the API, was accurately weighed and finely powdered. An amount equivalent to 10 mg of the API was transferred to a 25 mL volumetric flask. To this, 10 mL of a solvent mixture (acetonitrile:methanol:water in a 4:4:2 v/v/v ratio) was added. The mixture was sonicated for 20 minutes to facilitate complete extraction of the drug. After sonication, the solution was filtered through a 0.20 µm nylon membrane filter to remove any undissolved excipients. The filtrate was then analyzed using the HPLC system under the specified chromatographic conditions to assess drug recovery, ensuring the method's accuracy and reliability.

5. Sample Preparation for Linearity/Calibration Studies

Aliquots of the standard stock solution, corresponding to concentrations ranging from 32.15 µg/mL to 500 µg/mL of the API, were accurately measured and transferred into a series of 10 mL volumetric flasks. Each solution was diluted to volume with the mobile phase to achieve the desired concentrations. A 20 µL volume of each prepared solution was injected into the HPLC system. A calibration curve was constructed by plotting the peak area against the corresponding concentration of the API, facilitating the assessment of the method's linearity and sensitivity.

6. Precision Studies of the Proposed Method

The precision of the method was evaluated by analyzing nine replicates of the marketed formulation at a concentration of 100 µg/mL within the same day (intra-day precision). Additionally, the same concentration was analyzed over three consecutive days to assess inter-day precision. All analyses were conducted using the specified chromatographic conditions. The results were expressed as the relative standard deviation (%RSD) of the peak areas, providing an indication of the method's repeatability and reliability.

7. Robustness of the Chromatographic Method

The robustness of the method was assessed by deliberately varying critical chromatographic parameters and observing the effects on system suitability parameters such as retention time, peak tailing, capacity factor, resolution, and theoretical plates. The flow rate of the mobile phase was altered by ±0.1 mL/min from the optimal 1.0 mL/min to 0.9 mL/min and 1.1 mL/min. The proportion of acetonitrile in the mobile phase was adjusted by ±2% from 70% to 68% and 72%. Additionally, the detection wavelength was varied by ±2 nm from 230 nm to 228 nm and 232 nm. These deliberate variations were implemented to evaluate the method's robustness and its capacity to remain unaffected by small but deliberate changes in analytical conditions, ensuring its reliability under varied conditions.

8. System Suitability Parameters

Prior to analysis, system suitability tests were conducted to confirm the adequacy of the HPLC system for the intended analysis. Parameters such as resolution, tailing factor, theoretical plate count, and retention time were evaluated to ensure compliance with established criteria. These tests are essential to verify that the system's performance is appropriate for reliable and accurate analysis, thereby ensuring the validity of the analytical results.

CONCLUSION

The development and validation of the RP-HPLC method for analyzing the marketed tablet formulation have demonstrated that the method is simple, precise, and accurate. The method effectively separates the active pharmaceutical ingredient from excipients and potential impurities, ensuring reliable quantification. Validation parameters, including system suitability, linearity, precision, accuracy, and robustness, meet the acceptance criteria as per ICH guidelines. Therefore, this validated RP-HPLC method can be confidently employed for routine quality control analysis of the marketed tablet formulation, ensuring consistent product quality and efficacy.

REFERANCES

1. International Conference on Harmonisation (ICH). (2005). ICH Q2(R1) - Validation of Analytical Procedures: Text and Methodology. Retrieved from https://www.ich.org
2. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2011). Introduction to Modern Liquid Chromatography (3rd ed.). John Wiley & Sons.
3. Swartz, M. E., & Krull, I. S. (2012). Handbook of Analytical Validation. CRC Press.
4. Dong, M. W. (2006). Modern HPLC for Practicing Scientists. John Wiley & Sons.
5. Bhasker, T. V., &Venkateswarlu, G. (2020). Development and validation of a stability-indicating RP-HPLC method for pharmaceutical dosage forms. Journal of Pharmaceutical Sciences and Research, 12(6), 745-751.

6. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis, 4(3), 159–165.
7. Kazakevich, Y., &Lobrutto, R. (2007). HPLC for Pharmaceutical Scientists. John Wiley & Sons.
8. Bansal, G., &Baghel, U. S. (2014). Stability-indicating method development and validation for pharmaceutical analysis. Journal of Bioequivalence & Bioavailability, 6(3), 094-101.
9. European Medicines Agency (EMA). (2019). ICH guideline Q1A(R2) - Stability Testing of New Drug Substances and Products. Retrieved from https://www.ema.europa.eu
10. Dey, S., & Jain, N. (2018). A review on analytical method development and validation. Asian Journal of Pharmaceutical and Clinical Research, 11(2), 30–36.